ArticlePloS one2025
PRAME-AS lncRNA, regulated by MZF1, modulates PRAME expression and cell stemness.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PRAME promotes invasion and metastasis of salivary adenoid cystic carcinoma by regulating RARα stability via the cullin2 ubiquitin-proteasome system.Clinical and translational medicine · 2026Article
- DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PRAME is a member of the large cancer-testis antigens (CTA). In normal tissues, PRAME is mainly expressed in the testis. However, low levels of PRAME transcript are detected in the endometrium, ovary, and adrenal glands. Due to the tumor-restricted expression of PRAME, some of its regulatory factors have been investigated; however, the role of lncRNAs remains unclear. In this study, we ablated the PRAME-AS gene and investigated the effects on PRAME expression, cell proliferation, migration, viability, and anchorage-independent growth. We further manipulated PRAME-AS expression through MZF1 overexpression and hypermethylation of its upstream regulatory region. Additionally, we assessed the ability of the PRAME locus regulatory region to drive PRAME-AS lncRNA transcription. Our findings show that PRAME-AS gene knockout diminishes PRAME transcript levels by about 37%. The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. We discovered that MZF1 induces PRAME expression approximately twofold and increases PRAME-AS transcript levels by more than threefold. We found that hypermethylation of the upstream regulatory sequence of PRAME-AS results in an approximately 50% reduction in PRAME transcripts and an 18.5% decrease in PRAME-AS transcript levels. Moreover, based on our EGFP reporter assay, we conclude that the regulatory region of the PRAME locus-without PRAME transcription-is insufficient to drive transcription of PRAME-AS in the antisense direction. Taken together, our data support the conclusion that PRAME-AS lncRNA acts as a regulator of PRAME transcript levels, and that MZF1-and the methylation status of a shared CpG island- influence the expression of both genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.